Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer December 29, 2017Vol.40 No.11
PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma December 29, 2017Vol.40 No.11
Genentech’s Tecentriq and Avastin reduce the risk of disease worsening or death from RCC December 29, 2017Vol.40 No.11
Phase III study of venetoclax in combination with rituximab meets primary endpoint December 29, 2017Vol.40 No.11
Juno Therapeutics and Celgene release additional data from TRANSCEND trial December 29, 2017Vol.40 No.11
Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer December 29, 2017Vol.40 No.11
Drugs & Targets FDA approves adjuvant indication for Sutent in renal cell carcinoma December 07, 2017Vol.40 No.10
Ziopharm announces positive updated results of Ad-RTS-hIL-12 study in brain cancer December 07, 2017Vol.40 No.10
Clinical data for CXCR4 inhibitor, Inlyta showa 29% ORR in clear cell renal cell carcinoma December 07, 2017Vol.40 No.10
